{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:25:40Z","timestamp":1790144740749,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.bbmt.2018.09.038","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T02:23:59Z","timestamp":1538619839000},"page":"369-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":206,"title":["A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-8734","authenticated-orcid":false,"given":"Francisco M.","family":"Marty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew J.","family":"Winston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8921-8561","authenticated-orcid":false,"given":"Kathleen M.","family":"Mullane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsiporah B.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa A.","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Chittick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Brundage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion E.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Garrett","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Boeckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.09.038_bib0001","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0002","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.idc.2010.01.008","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"24","author":"Ljungman","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0003","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0004","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1365-2141.2001.02519.x","article-title":"Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis","volume":"112","author":"Craddock","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0006","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0007","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","article-title":"Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis","volume":"110","author":"Marty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0008","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu364","article-title":"Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation","volume":"59","author":"Ljungman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0009","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0010","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0011","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0012","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0013","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0014","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coviro.2011.10.011","article-title":"Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?","volume":"1","author":"Marty","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0016","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0017","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1128\/AAC.48.12.4745-4753.2004","article-title":"Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0018","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1086\/421912","article-title":"Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection","volume":"190","author":"Bidanset","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0019","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2014.10.005","article-title":"Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model","volume":"112","author":"Tollefson","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0021","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0022","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1086\/656717","article-title":"Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies","volume":"202","author":"Quenelle","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0023","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.46.4.991-995.2002","article-title":"Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir","volume":"46","author":"Kern","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0024","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1128\/AAC.00184-07","article-title":"Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/v3020063","article-title":"Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans","volume":"3","author":"Rice","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0026","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/v3010047","article-title":"Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans","volume":"3","author":"Rice","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0027","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2015.02.007","article-title":"The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease","volume":"117","author":"Trost","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0028","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.antiviral.2017.04.002","article-title":"Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits","volume":"143","author":"Grossi","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0029","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1128\/AAC.50.4.1564-1566.2006","article-title":"Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro","volume":"50","author":"Randhawa","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0030","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1128\/AAC.01241-07","article-title":"Anti-BK virus activity of nucleoside analogs","volume":"52","author":"Randhawa","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0031","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1600-6143.2008.02269.x","article-title":"Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression","volume":"8","author":"Bernhoff","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0032","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.00046-11","article-title":"CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes","volume":"55","author":"Gosert","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0033","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0034","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0035","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1124\/mol.63.3.678","article-title":"Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism","volume":"63","author":"Aldern","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0036","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0037","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/FTD.0000000000000353","article-title":"Brincidofovir is not a substrate for the human organic anion transporter 1: a mechanistic explanation for the lack of nephrotoxicity observed in clinical studies","volume":"38","author":"Tippin","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0038","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0039","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cid\/cix804","article-title":"Kinetics of double-stranded DNA viremia after allogeneic hematopoietic cell transplantation","volume":"66","author":"Hill","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0040","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.bbmt.2018.09.038_bib0041","first-page":"S327","article-title":"Pre-engraftment initiation of brincidofovir (CMX001) in hematopoietic cell transplant (HCT) recipients is supported by lack of myeloid toxicity","volume":"49","author":"Papanicolaou","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0042","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0043","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0044","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed March 17, 2018."},{"key":"10.1016\/j.bbmt.2018.09.038_bib0045","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00000478-197908000-00001","article-title":"Gastrointestinal graft-versus-host disease in man: a clinicopathologic study of the rectal biopsy","volume":"3","author":"Sale","year":"1979","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0046","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2006-01-0254","article-title":"An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens","volume":"108","author":"Leisenring","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0047","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00428-015-1803-y","article-title":"Consensus diagnostic histopathological criteria for acute gastrointestinal graft-versus- host disease improve interobserver reproducibility","volume":"467","author":"Kreft","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0048","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1432-2277.2005.00218.x","article-title":"The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy","volume":"19","author":"Marty","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0049","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/tid.12447","article-title":"It's not too late: a proposal to standardize the terminology of \u201clate-onset\u201d cytomegalovirus infection and disease in solid organ transplant recipients","volume":"17","author":"Razonable","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0050","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2015-10-612747","article-title":"How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver","volume":"127","author":"McDonald","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0051","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/106689690301100406","article-title":"Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern","volume":"11","author":"Papadimitriou","year":"2003","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0052","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/modpathol.2009.44","article-title":"Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil","volume":"22","author":"Selbst","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0053","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1097\/MPH.0000000000001227","article-title":"Brincidofovir (CMX001) toxicity associated with epithelial apoptosis and crypt drop out in a hematopoietic cell transplant patient: challenges in distinguishing drug toxicity from GVHD","volume":"40","author":"Detweiler","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0054","unstructured":"U.S. National Library of Medicine. SUSTAIN: a randomized, double-blind, multicenter, phase 3 study of the efficacy, safety, and tolerability of brincidofovir versus valganciclovir for the prevention of cytomegalovirus disease in CMV seronegative kidney allograft recipients (BCV CMV vGCV). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02439970. Accessed April 3, 2018."},{"key":"10.1016\/j.bbmt.2018.09.038_bib0055","first-page":"e269","article-title":"Co-administration of cyclosporine (CsA) increases plasma brincidofovir (BCV) exposure in healthy volunteers","volume":"36","author":"Wire","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0056","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0057","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0058","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bbmt.2011.09.007","article-title":"Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients","volume":"18","author":"Florescu","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0059","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1016\/j.bbmt.2011.12.286","article-title":"Cmx001 as therapy for severe adenovirus infections in immunocompromised pediatric patients: single experience in 5 patients","volume":"18","author":"Grimley","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.antiviral.2017.01.009","article-title":"Short-term clinical safety profile of brincidofovir: a favorable benefit-risk proposition in the treatment of smallpox","volume":"143","author":"Chittick","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0061","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","article-title":"Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial","volume":"23","author":"Grimley","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0062","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcv.2017.09.013","article-title":"Disseminated adenovirus infection after allogeneic stem cell transplant and the potential role of brincidofovir: case series and 10-year experience of management in an adult transplant cohort","volume":"96","author":"Ramsay","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0063","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2016-11-749721","article-title":"Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant","volume":"129","author":"Hiwarkar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.038_bib0064","doi-asserted-by":"crossref","first-page":"9603","DOI":"10.1007\/s11357-013-9603-2","article-title":"Aging of the mammalian gastrointestinal tract: a complex organ system","volume":"36","author":"Saffrey","year":"2014","journal-title":"Age (Dordr)"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2018.09.038_bib0065","article-title":"Pharmacokinetics (PK) and safety of intravenous (IV) brincidofovir (BCV) in healthy adult subjects","volume":"4","author":"Wire","year":"2017","journal-title":"Open Forum Infect Dis"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118306050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118306050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:04:20Z","timestamp":1761059060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118306050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1083879118306050"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.038","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}